These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 18937966

  • 1. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
    Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, Soper JT, Havrilesky L.
    Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
    [Abstract] [Full Text] [Related]

  • 2. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
    Otsuka I, Takahashi S, O'uchi K, Akimoto N, Hanari K, Ogaki Y, Enatsu YH, Takigawa A, Takaya H, Tanaka A, Kaseki H, Yamada T.
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
    [Abstract] [Full Text] [Related]

  • 3. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study Group.
    J Natl Cancer Inst; 2005 Mar 02; 97(5):375-84. PubMed ID: 15741574
    [Abstract] [Full Text] [Related]

  • 4. Association between uterine serous carcinoma and breast cancer.
    Gehrig PA, Bae-Jump VL, Boggess JF, Groben PA, Fowler WC, Van Le L.
    Gynecol Oncol; 2004 Jul 02; 94(1):208-11. PubMed ID: 15262144
    [Abstract] [Full Text] [Related]

  • 5. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
    Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH.
    Obstet Gynecol; 2004 Aug 02; 104(2):255-60. PubMed ID: 15291996
    [Abstract] [Full Text] [Related]

  • 6. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.
    Hachisuga T, Saito T, Kigawa J, Ohwada M, Yamazawa K, Yasue A, Iwasaka T, Sugiyama T, Kita T, Nagai N.
    Gynecol Oncol; 2004 Oct 02; 95(1):139-44. PubMed ID: 15385123
    [Abstract] [Full Text] [Related]

  • 7. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.
    Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F.
    Cancer; 1998 May 01; 82(9):1698-703. PubMed ID: 9576291
    [Abstract] [Full Text] [Related]

  • 8. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.
    Saadat M, Truong PT, Kader HA, Speers CH, Berthelet E, McMurtrie E, Olivotto IA.
    Cancer; 2007 Jul 01; 110(1):31-7. PubMed ID: 17510927
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
    Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, Van Robaeys J, Neven P, Moerman P, Vergote I.
    Gynecol Oncol; 2005 Aug 01; 98(2):274-80. PubMed ID: 15972232
    [Abstract] [Full Text] [Related]

  • 11. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
    Olson SH, Finstad CL, Harlap S, Kurian L, Saigo PE, Barakat RR.
    Cancer Epidemiol Biomarkers Prev; 1997 Oct 01; 6(10):815-7. PubMed ID: 9332764
    [Abstract] [Full Text] [Related]

  • 12. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features.
    Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ.
    Gynecol Oncol; 1994 Nov 01; 55(2):164-8. PubMed ID: 7959278
    [Abstract] [Full Text] [Related]

  • 13. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
    Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F.
    Gynecol Oncol; 2000 Aug 01; 78(2):181-6. PubMed ID: 10926800
    [Abstract] [Full Text] [Related]

  • 14. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
    Semiglazov VF, Maksimov SIa, Bulgatova EA, Meshkova IE, Chepik OF, Berstein LM.
    Vopr Onkol; 2003 Aug 01; 49(2):198-204. PubMed ID: 12785205
    [Abstract] [Full Text] [Related]

  • 15. Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer.
    Peters-Engl C, Medl M, Danmayr E, Mirau M, Alth G, Leodolter S.
    Anticancer Res; 1996 Aug 01; 16(5B):3241-6. PubMed ID: 8920798
    [Abstract] [Full Text] [Related]

  • 16. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
    Giordano G, Gnetti L, Merisio C, Melpignano M.
    Maturitas; 2007 Feb 20; 56(2):190-7. PubMed ID: 16963204
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
    Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, de Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE, Comprehensive Cancer Centers TAMARISK-group.
    Breast Cancer Res Treat; 2008 Nov 20; 112(1):99-108. PubMed ID: 18064567
    [Abstract] [Full Text] [Related]

  • 19. Comparison of uterine malignancies that develop during and following tamoxifen therapy.
    Ferguson SE, Soslow RA, Amsterdam A, Barakat RR.
    Gynecol Oncol; 2006 May 20; 101(2):322-6. PubMed ID: 16352333
    [Abstract] [Full Text] [Related]

  • 20. Tamoxifen, screening and new oestrogen receptor modulators.
    Neven P, Vergote I.
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun 20; 15(3):365-80. PubMed ID: 11476559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.